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Rationale: Much of the total disease burden and cost of chronic
obstructive pulmonary disease (COPD) is associated with acute exac-
erbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel
candidateexacerbationbiomarker identifiedbyproteomic screening.
Objectives: To assess SAA as a biomarker of AECOPD.
Methods: Biomarkers were assessed (1) cross-sectionally (stable vs.
AECOPD; 62 individuals) and (2) longitudinally with repeated
measures (baseline vs. AECOPD vs. convalescence; 78 episodes in
37 individuals). Event severity was graded (I, ambulatory; II, hospi-
talized; III, respiratory failure) based on consensus guidelines.
Measurements andMainResults: Presumptivelynewlyacquiredpatho-
gens were associated with onset of symptomatic AECOPD. In the
cross-sectional study, both SAA and C-reactive protein (CRP) were
elevated at AECOPD onset compared with stable disease (SAA
median, 7.7 vs. 57.6 mg/L; P , 0.01; CRP median, 4.6 vs. 12.5 mg/L;
P,0.01). Receiver operator characteristics analysiswas used togen-
erate area-under-curve values for event severity. SAA discriminated
level II/III events (SAA, 0.88; 95% confidence interval, 0.80–0.94 vs.
CRP, 0.80; 95%confidence interval, 0.70–0.87; P50.05). Combining
SAAor CRPwithmajor symptoms (Anthonisen criteria, dyspnea) did
not further improve the prediction model for severe episodes. IL-6
and procalcitonin were not informative.
Conclusions: SAA is a novel blood biomarker of AECOPD that is more
sensitive than CRP alone or in combination with dyspnea. SAA may
offer new insights into the pathogenesis of AECOPD.
Keywords: chronic obstructive pulmonary disease; exacerbation;
biomarker; inflammation
Chronic obstructive pulmonary disease (COPD) is nowoneof the
leading causes ofmortality andmorbidity worldwide (1). Patients
with moderate to severe COPD are particularly susceptible
to recurrent acute exacerbations of COPD (AECOPD), which
account for much of the total disease burden. AECOPD have
been associated with accelerated decline in lung function (2),
increased morbidity, decreased quality of life (3), and increased
mortality, often from later cardiovascular system events (4). In
most health care systems, AECOPD are also the major cost
component of the disease, particularly if they lead to subsequent
hospitalization (5, 6). Despite their importance, AECOPD and
their severity remain difficult to define objectively.AECOPDare
therefore usually defined operationally as ‘‘a sustainedworsening
of the patient’s condition that is acute in nature and necessitates
change in regular medication’’ (7) and/or by increased consump-
tion of health care resources (8). In this study, we used the
American Thoracic Society/European Respiratory Society
(ATS/ERS) consensus definition (‘‘an acute change in a patient’s
baseline dyspnea, cough, and/or sputum beyond day-to-day
variability sufficient to warrant a change in therapy’’) to define
exacerbations, and the ATS/ERS exacerbation severity grades:
level I, ambulatory; level II, hospitalization; and level III, re-
spiratory failure (9).
The majority of AECOPD are known to be associated with
acute respiratory tract infection, although some may also be
triggered by pollutants, cold weather, or irritants (10). Respira-
tory viral infection and the acquisition of a new bacterial strain
have both been characterized in AECOPD (11, 12). AECOPD
caused by pathogens are associated with increased lung and
systemic inflammation (13, 14). This increase in inflammation
has opened the possibility of finding systemic biomarkers of
disease induced by inflammatory mediators. Recently, consider-
able attentionhas focusedonC-reactiveprotein (CRP), ahepatic,
acute-phase protein induced by inflammatory mediators, such as
IL-6, IL-1b, and tumor necrosis factor (TNF)-a, and the level of
which, consequently, reflects inflammation. The potential utility
of biomarkers is reflected in the observations that basal CRP
levels are related to lung function decline (15). CRP may also be
a marker of comorbid cardiovascular disease and mortality risk;
in addition, CRP levels rise in AECOPD (16, 17).
On the basis of evidence that AECOPD are associated with
systemic inflammation, in forerunner experiments to this study,
we used a highly sensitive, but nonquantitative, surface-enhanced
laser desorption ionization time-of-flight (SELDI-ToF) proteo-
mics method to screen for novel candidate biomarkers in an
AECOPD serum collection. We found an 11,699-D protein mass
peak corresponding to serum amyloid A (SAA) in the sera of
patients with elevated CRPwho had been hospitalized for severe
AECOPD (see the online supplement). Because the association
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Inflammatory and other markers are currently being eval-
uated for their predictive value in exacerbations of chronic
obstructive pulmonary disease.
What This Study Adds to the Field
SerumamyloidAappears tobebetter related toevent severity
in acute exacerbations of COPD than is C-reactive protein.
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of SAAwith AECOPD or AECOPD severity has not previously
been reported, SAA was selected for prospective validation
studies.
SAA is an acute-phase protein, induced, like CRP, by in-
flammatory mediators, including IL-6, IL-1b, and TNF-a, that
rise acutely in AECOPD (18). SAA is secreted from the liver as
the predominant apolipoprotein associated with plasma high-
density lipoprotein cholesterol. The human SAA gene family is
comprised of fourmembers: SAA1 and SAA2 are induced during
inflammation or in response to tissue injury; SAA3 is a pseudo-
gene; and SAA4 is constitutively expressed.
Because SELDI-ToF is semiquantitative and poorly suited to
repeat-measurement studies, we have used quantitativemeasure-
ments of SAA by an ELISA assay, which detects induced SAA1
and SAA2 to compare the sensitivity and specificity of SAA to
CRP, IL-6, and procalcitonin as biomarkers of AECOPD, both
cross-sectionally and longitudinally. Furthermore, we analyzed
whether SAA was better associated with event severity than was
CRP and other putative biomarkers. Our data suggest that SAA
is a systemic biomarker of AECOPD that contrasts favorably
with CRP, whethermeasured alone or used in concert withmajor
symptoms of exacerbations. As the biology of SAA differs sub-
stantially from CRP, our study may also offer new insights into
the pathogenesis of AECOPD and their sequalae. We have
previously presented some parts of the present study in abstract
form (19).
METHODS
Patientswere recruited from theMelbourneLongitudinalCOPDCohort
(MLCC), an open cohort of participants with moderate to severe COPD
(GOLD [Global Initiative for ChronicObstructive LungDisease] stages
II–IV). The MLCC is comprised of patients who have previously pre-
sented with acute severe AECOPD to the Royal Melbourne Hospital
(RMH) inMelbourne, Australia. After discharge, patients in theMLCC
are routinely managed in the community by practice nurses in consulta-
tion with chest physicians based at RMH and local general physicians.
Additional subjects for cross-sectional analysis were recruited from
patients presenting with acuteAECOPD at RMHor at general practice.
In addition, baseline SAA and CRP values were also obtained in nine
age-matched, healthy volunteers and nine patients with obstructive sleep
apnea recruited from the RMH sleep clinic.
Study Design
The primary objective of the study was to test the hypothesis that SAA is
a blood biomarker, the level of which rises during infectious AECOPD.
The secondary objective of the study was to relate changes in SAA to
event severity in comparison with CRP, other putative biomarkers, and
standard clinical assessment. We report a cross-sectional analysis at two
time points (coinciding with stable COPD andAECOPD) in 62 patients
for 62 events. We also report a more detailed longitudinal study of 37
patients for 78 events (measured at three time points: stable COPD,
AECOPD, and recovery) with virological and microbiological assess-
ment, including respiratory viruses (multiplex polymerase chain reaction
[PCR], atypical pneumonia serology, sputum [if available] for bacterial
culture, and serum collection). A patient flow chart is shown in Figure 1,
and their characteristics and regular treatment are reported in Table 1.
Inclusion criteria were stable, moderate to severe COPD (GOLD
criteria). Baseline data from patients with clinically stable disease
includeddemographics, spirometry, carbonmonoxidediffusing capacity,
exercise tolerance, and symptom severity. Exclusion criteria were living
more than 50 kilometers from the hospital, lung cancer, chronic systemic
inflammatory conditions, renal failure requiringdialysis, and theneed for
palliative care. The Human Research Ethics Committee of Melbourne
Health (Royal Melbourne Hospital) approved the study, and written
informed consent was obtained from all subjects.
In the community-based longitudinal study, identification of exacer-
bations at an early stage was achieved by use of individualized patient
action plans, with instructions to contact the study team when key
AECOPD symptoms developed.Worsening of symptomswas defined as
an increase in symptom severity from each patient’s baseline values for
more than 24 hours (see the online supplement). Full clinical assessment
(including oximetry) was performed at home by experienced respiratory
outreach nurses. A score for the presence of viral symptoms was
performed on Days 1 and 5 of each exacerbation, assessing rhinorrhea,
Figure 1. Study design flow chart. A total of 62 patients experiencing
their first acute exacerbations of chronic obstructive pulmonary disease
(AECOPD) were studied in the cross-sectional study (top). A total of 37
of these patients were recruited to a prospective longitudinal study. In
the longitudinal study, 15 (41%) had 1 AECOPD, 12 (32%) experienced
2 AECOPD, and 10 (27%) experienced 3–5 AECOPD. Event severity
(level I–III) was determined according to ATS/ERS consensus guidelines.
For the purpose of statistical analysis, only first events were included in
data analyzed in the main text. Further details of analysis of multiple
events are presented in the online supplement.
TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS
Baseline Characteristics Value
Age, yr (range) 71 (56–86)
Sex, male:female, n (%) 36 (58):26 (42)
GOLD severity class, n (%)
2 7 (11)
3 21 (34)
4 34 (55)
Post-BD FEV1, L (range) 1.02 (0.5–3.4)
FEV1 % predicted, % (range) 35 (20–56)
Domiciliary oxygen, n (%) 16 (26)
Hypercapnia, n (%) 9 (15)
Pack-years smoking, yr (range) 52 (10–160)
Current smoker, n (%) 16 (26)
Chronic bronchitis, n (%) 54 (90)
Ischemic heart disease, n (%) 11 (17)
Chronic heart failure, n (%) 17 (27)
Obstructive sleep apnea, n (%) 5 (8)
Usual COPD medications, n (%)
Short-acting b-agonist 62 (100)
Inhaled anticholinergic* 62 (100)
Combination inhalers† 58 (94)
Low-dose oral steroids 4 (6)
Oral theophyllines 2 (3)
Definition of abbreviations: BD 5 bronchodilator; COPD 5 chronic obstructive
pulmonary disease; GOLD 5 Global Initiative for Chronic Obstructive Lung
Disease.
* A total of 96% of these patients received tiotropium and 4% received
ipratropium.
† A total of 96% of these patients were treated with salmeterol-fluticosone and
4% received formoterol-budesonide.
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nasal congestion, sore throat, myalgia or headaches, subjective fever,
chills, or rigors (20–22). Patients were referred to hospital for additional
assessments (chest X-ray and arterial blood gases) if their oxygen
saturation was less than 88% on room air or usual domiciliary oxygen
therapy, or there was clinical evidence of pneumonia, severe respiratory
distress, or altered mental status.
Acute Effect of Oral Steroids
We directly tested whether oral steroids altered SAA or CRP in
a separate analysis in a group of eight patients admitted for AECOPD
in order to formally assess this potentially confounding variable. Blood
was collected at four timepoints: (1)when stable; (2) on admissionbefore
steroid administration (100 mg i.v. hydrocortisone three times a day or
25–50 mg p.o. prednisolone; (3) 24 hours after steroids administration;
and (4), when available, a recovery sample was collected.
Definition and Severity Grading of Exacerbations
Stable COPD was defined as no requirement for increased treatment
above maintenance therapy, other than bronchodilators, for 30 days.
AECOPD were defined by ATS/ERS consensus criteria (8), and also
met the Anthonisen criteria; (i.e., increased dyspnea, increased sputum
purulence or amount or increased dyspnea accompanied by signs of
viral upper respiratory tract infection) (23). Resolution of an AECOPD
was defined as: (1) completion of treatment with antibiotics and
increased steroids; (2) return of symptoms to baseline levels for 48
hours; or (3), if symptoms had not fully resolved within 30 days of
onset, that symptoms were stable for 48 hours and did not require
further acute treatment.
Grading of exacerbation severity. Peak clinical severity reached
between Days 1 and 14 of each exacerbation episode was used as the
severity outcome. At resolution, the overall exacerbation severity was
coded as the maximum severity of each episode. We used the ATS/
ERS consensus operational criteria to grade severity as follows:
ambulatory (level I); requiring hospitalization (level II); and acute
respiratory failure (level III) (9). Chest X-ray was performed if there
was clinical evidence of pneumonia.
Virology and Microbiology
Respiratory virus multiplex PCR and atypical serology were performed
at the Victorian Infectious Disease Reference Laboratory (24), a World
Health Organization reference laboratory. Nose and throat swabs for
multiplex PCR were collected at onset of the episode (Days 1–5). The
following viruses were screened: influenza A and B; picornavirus
(rhinovirus); respiratory syncytial virus (RSV); parainfluenza; and
adenovirus (24). Spontaneously expectorated sputum samples were
obtained at AECOPD onset. In patients who were chronically colo-
nized with potentially pathogenic bacteria, increased color and amount
of sputum (25), or a change in pathogen detected on sputum culture,
was used to indicate an AECOPD. Bacteria cultured from sputum with
a bacterial load of at least 2 3 102 cfu were coded as bacteria positive.
Sputum microscopy and culture were performed by the clinical di-
agnostic laboratory, Melbourne Pathology, using standard techniques.
Blood was obtained on Days 1 and 30 of each AECOPD and screened
for antibodies for influenza A and B, Chlamydia pneumoniae,
C. psittaci, Legionella pneumophila, and Mycoplasma pneumoniae (24).
An AECOPD associated with an atypical pathogen was defined as at
least a fourfold rise in serum antibody titer between the Day-1 and
Day-30 specimens.
Measurement of Inflammatory Serum Markers
Measurements were performed blinded and independently from the
clinical and microbiological assessment of exacerbations using standard
clinical tests. CRP was first assessed by immunoturbidimetry (detection
range, 5–300 mg/L; values . 300 mg/L were obtained by automated di-
lution; Olympus Diagnostica GmbH, Hamburg, Germany). CRP values
below 5 mg/L were determined by high-sensitivity ELISA (detection
limit, 0.35 ng/ml; Alpha Diagnostics, San Antonio, TX). ELISA was used
to determine SAA (detection limit, 1.1 ng/ml; Anogen, Mississauga, ON,
Canada) and IL-6 (OptEIA ELISA, detection limit, 4.7 pg/ml; Becton-
Dickinson, San Diego, CA). Procalcitonin was determined by immuno-
lumunometric assay (PCT LIA, detection limit, 0.3 ng/ml; BRAHMS,
Henningsdorf, Germany). SAA is composed of four family members
(SAA1–SAA4), with only SAA1 and SAA2 induced during the acute
response (26). The assay we used identifies both SAA1 and SAA2.
Identification of SAA by SELDI-ToF Proteomics
See Figure 2 and the online supplement for details.
Statistical Analyses
The distributions of SAA and CRP values were log-normal, and data
were natural logarithm transformed. Data are presented as median and
interquartile range with 95% confidence interval (CI). Analyses of key
findings are also reported for absolute values.
Analysis of cross-sectional study. In the cross-sectional study of 62
AECOPD (one AECOPD event per patient with COPD, obstructive
sleep apnea, and normal reference groups), the difference in loge(SAA)
and loge(CRP) between stable COPD, reference groups, and AECOPD
was assessed using analysis of variance. These data are reported in
Figure 3. Tomeasure whether there was a significant difference in themag-
nitude of change in CRP and SAA associated with milder community-
managed AECOPD (level 1) and AECOPD requiring hospitalization
(level II/III), the change in loge(SAA) and loge(CRP) was compared
between groups using unpaired t tests. To determine whether SAA and
CRP differentiated between stable COPD and AECOPD onset, the
area under the curve (AUC) receiver operating characteristics (ROC)
for each marker was analyzed, first to differentiate level I AECOPD
from stable COPD, and second to differentiate level II/III from stable
COPD. Absolute SAA and CRP values were used in this analysis so that
potential diagnostic cutoffs could be evaluated. These data are reported
in Figure 4.
Acute effect of oral glucocorticosteroids on biomarker levels over 24
hours. The effect of steroids on biomarker levels was assessed by
paired t test. These data are reported in Figure 5.
Figure 2. Surface-enhanced laser desorption ionization
time-of-flight (SELDI-ToF) ProteinChip analysis. The top
panel of each pair is a representative mass spectral serum
profile from exacerbating samples (acute exacerbations of
chronic obstructive pulmonary disease [AECOPD]) or
stable samples (Stable) subjected to SELDI-ToF mass
spectrometry, as detailed in METHODS (n 5 4). The bottom
panel of each pair is a pseudogel image (pseudogel) of the
spectral profiles showing relative abundance and identify-
ing a cluster of proteins approximately 11.7 kD in size
(rectangle) induced during an AECOPD, which correspond
to the molecular weight of serum amyloid A (SAA).
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Analysis of longitudinal study. First, in the longitudinal study of 78
AECOPD from 37 individuals, the change in SAA and CRP between
stable COPD, AECOPD, and recovery was assessed by analysis of
variance of log data, and is reported in Figure 6. As AECOPD severity
increases with increasing disease severity, it is easily conceivable that
repeatedAECOPDin a subset of patients could skew thedata; therefore,
the primary analysis of these data was restricted to one AECOPD (first
event) per patient. Second, to analyze repeatedAECOPDepisodes from
the same patient, a further statisticalmodel that allows forwithin-subject
correlation of repeated measures (both within-exacerbation and be-
tween-exacerbations) was applied. The statistical methodology used was
a linear regression model based upon a generalized estimating equation
(GEE) with an exchangeable correlation structure and robust standard
errors (27). Theprimaryanalysis ofwithin-subject changewas stringently
restricted to one exacerbationper subject, but the results and conclusions
were similar when the analysis incorporated multiple exacerbations on
individual subjects (allowing for correlation within subjects over re-
peated exacerbations). These data and further details of GEE analysis
are presented in the online supplement.
Analysis of relationship between biomarkers and severity of
AECOPD. CRP is known to be elevated in stable COPD (28, 29). To
control for raised blood marker levels in stable disease, a difference score
was generated as the difference between log-transformed values at
AECOPD onset compared with stable disease. For the initial analysis,
severity was defined as an ordered three-level categorical outcome (i.e.,
ATS/ERS levels I, II, and III), and analyzed using an ordinal logistic
regression model. Cluster analysis by patient was used to adjust the
regression models for repeated AECOPD episodes where they occurred
in the samepatient during the course of the study.Amultivariable, ordinal
logistic regression model that included FEV1 % predicted was then
developed to adjust for between-patient differences in the underlying
disease severity and susceptibility to more severe AECOPD. To deter-
mine cutoff values for blood marker levels to potentially predict severe
AECOPD, severity was subsequently defined as a binary categorical
outcome (level I vs. level II/III) (30). AUC ROC analysis was used to
measure theutilityofCRPandSAAtopredictAECOPDseverity.Results
of this analysis are presented as both absolute values at AECOPD onset
and as within-patient change from values obtained in stable COPD.AUC
ROC curves were compared using the Stata version 8.2 ‘‘Roccomp’’
command (StataCorp LP, College Station, TX), which controls the
standard error for correlations between the two tests using the same set
of samples. The discriminative value of blood inflammatory markers to
determineAECOPD severity was also compared to change from baseline
values in severity of dyspnea, sputumpurulence, and sputumamount using
logistic regression. These data are reported in the subsequent text.
AECOPD Etiology
AECOPD were coded as ‘‘bacterial’’ or ‘‘nonbacterial’’ according to
whether a new bacterium was isolated on sputum culture. Median
values in each group were compared using Wilcoxon rank sum test.
Logistic regression was used to determine whether the difference
(between AECOPD onset and stable COPD) in loge(CRP) and
loge(SAA) were discriminative of AECOPD etiology.
All statistics were analyzed using the Stata version 8.2 statistical
package and Prism version 4 (GraphPad Software, Inc., San Diego, CA).
RESULTS
SAA Proteomics
SAA was initially identified as a candidate biomarker by
SELDI-ToF proteomics (see Figure E2 in the online supple-
Figure 3. Serum amyloid A (SAA_ and C-reactive protein (CRP) levels
during acute exacerbations of chronic obstructive pulmonary disease
(AECOPD) compared with stable COPD, obstructive sleep apnea
(OSA), and normal control samples. (A) SAA and (B) CRP absolute
values (mg/L) are presented from the cross-sectional study (n 5 62
AECOPD; n 5 62 stable; n 5 9 normal; and n 5 9 OSA samples). The
horizontal bar denotes mean values. #P , 0.05, compared to stable
samples, analysis of variance. Note the broken axis.
Figure 4. Serum amyloid A (SAA) and C-reactive protein (CRP) levels in
acute exacerbation of chronic obstructive pulmonary disease
(AECOPD) severity grade I versus II/III. (A) SAA (open boxes) and CRP
(gray boxes) graphically represent median and 95% confidence interval
(CI) with error bars corresponding to the interquartile range for the
change (D, stable to AECOPD) in loge-transformed levels (mg/L)
plotted by AECOPD severity grade. (B) Receiver operating character-
istics (ROC) curve was generated by comparing absolute stable values
for SAA and CRP to their corresponding AECOPD values, which have
been stratified on the basis of overall event severity (level I, community-
managed event; level II, hospitalization; level III, respiratory failure).
The SAA level II/III ROC value was significantly different from all other
parameters, with an area-under-curve value of 0.881 (95% CI, 0.80–
0.94). For full ROC analysis, see the online supplement.
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ment). Further studies on SAA presented subsequently here
were performed prospectively with quantitative ELISA.
Cross-sectional Study: Patient and AECOPD Characterization
The first AECOPD event occurring following recruitment in
a total of 62 patients was included in this analysis. Participants’
baseline characteristics and regular treatment are shown in
Table 1. Spirometry confirmed that all patients had moderate to
severe COPD (GOLD II–IV); mean FEV1 was 35% predicted
(range, 20–56%), and reversibility was less than 15%. A total of
26% of patients were on long-term home oxygen. Mean pack-
years of smoking was 52 (range, 10–160 pack-years), and 26%
was current smokers. For comparison, inflammatory marker
levels were also obtained in 18 age-matched control subjects
without COPD, 9 healthy volunteers, and 9 patients attending
the outpatient sleep disorders clinic (Figure 3). A total of 62
AECOPD was included in this analysis; 31 (50%) events were
level I, and were therefore managed in the community with oral
antibiotics and corticosteroids, and 31 (50%) required hospital-
ization (level II/III).
Serum CRP and SAA Levels during an AECOPD
The firstAECOPDper patient (62 patients and 62AECOPDfirst
events) was included in the primary analysis. Mean time from
AECOPD onset to obtaining serum for measurement of inflam-
matory markers was 6.2 days. SAA and CRP were elevated at
exacerbation onset compared with stable disease (SAA median:
stable COPD, 7.7 mg/L vs. AECOPD, 57.6 mg/L [P, 0.01]; CRP
median: stable COPD, 4.6 mg/L vs. AECOPD, 12.5 mg/L [P ,
0.01]) (Figure 3).
AECOPD severity and change in SAA and CRP at event
onset. Only SAA was significantly elevated in level II/III events
vs. level I (Figure 4A). Median change in SAA level II/III
events was 2.12 mg/L (95% CI, 1.80–3.21 mg/L) versus level I
events (1.23 mg/L; 95% CI, 0.56–2.05 mg/L) (P , 0.05). No
significant difference in CRP level I events (0.63 mg/L; 95% CI,
0.30–1.47) versus level II/III events (1.49 mg/L; 95% CI, 0.81–
2.0) was observed (Figure 4A). ROC curves are useful to assess
possible diagnostic cut-off point(s) for biomarker levels. Both
markers modestly distinguished level I AECOPD from stable
COPD, as ROC analysis generated AUC values of 0.71 (95%
CI, 0.61–0.80) for SAA and 0.66 (95% CI, 0.56-0.76) for CRP.
SAA was significantly better at differentiating level II/III
AECOPD from stable COPD with an AUC value of 0.88
(95% CI, 0.80-94) versus CRP with an AUC value of 0.80
(95% CI, 0.70–0.87) (P 5 0.05; see Figure E4B and the online
supplement). A biomarker cut-off of 12.5 mg/L was 87%
sensitive for severe AECOPD with a negative predictive value
of 92% for SAA and 54% sensitive with a negative predictive
value of 79% for CRP.
Effect of oral glucocorticosteroids. Oral glucocorticosteroids
neither acutely enhanced nor suppressed biomarker levels
significantly (Figure 5).
Longitudinal Community-based Cohort
A total of 78 AECOPD from 37 patients were assessed, with
63% of patients exacerbating more than once during the study
period. Participants’ baseline characteristics and regular treat-
ment are shown in Table E1. Spirometry confirmed that all
patients had moderate to severe COPD (GOLD II–IV); mean
FEV1 was 41% predicted (range, 15–69%), and mean FEV1/
FVC ratio was 45% (24–69%). Reversibility was less than 15%.
A total of 24% were on long-term home oxygen, mean pack-years
Figure 5. Steroids do not significantly alter serum amyloid A (SAA) and
C-reactive protein (CRP) levels during acute exacerbations of chronic
obstructive pulmonary disease (AECOPD). SAA (A) and CRP (B) levels
were assessed in eight patients with AECOPD treated with 25–50 mg
prednisolone (n 5 7) and 300 mg intravenous hydrocortisone (n 5 1).
Serum samples were measured at stable condition, immediately before
treatment (Pre), and 24 hours after steroid administration. Most
patients consented to a Day 30 recovery sample (n 5 5). Individual
patient data are shown. Bars denote mean values. No significant
difference was observed between pre- and post-steroid samples
(matched-pairs t test).
Figure 6. Longitudinal analysis confirmed within-subject increase in
serum amyloid A (SAA) and C-reactive protein (CRP) during an acute
exacerbation of chronic obstructive pulmonary disease (AECOPD).
Absolute values (mg/L) for (A) SAA and (B) CRP for ‘‘first event’’
AECOPD episodes compared with patient-matched stable and recovery
samples are presented. Bars denote mean values. #P , 0.05, analysis
of variance.
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of smoking was 45 (range, 10–115 pack-years), and 16% were
current smokers.
Exacerbation characteristics. The mean time of 2.4 days
from symptom onset to obtaining serum for measurement of
inflammatory markers was shorter than that for the cross-
sectional study. Figure 6 includes single first events only, and
shows that both SAA and CRP rose significantly during
AECOPD and then resolved: SAA stable COPD, 6.81 mg/L
(95% CI, 7.1–19.3); AECOPD, 68.00 mg/L (95% CI, 50.9–
601.4); recovery, 4.41 mg/L (95% CI, 0.5–58.0); CRP stable
COPD, 6.0 mg/L (95% CI, 4.6–13.1); AECOPD, 13.0 mg/L
(95% CI, 11.9–52.0); recovery, 4.0 mg/L (95% CI, 2.2–28.7).
Figure 7 presents a descriptive account of four randomly
selected patients experiencing multiple AECOPD. Although
the severity of underlying COPD is a known predictor of
AECOPD severity, it is noteworthy that biomarker changes
are reflected in individual AECOPD severity events, and that
CRP and SAA are not always concordant.
Inflammatory markers and AECOPD etiology. The likelihood
of detecting a pathogen increased with AECOPD severity.
Presumptively newly acquired pathogens at AECOPD onset
were detected (Figure 8A); respiratory viruses were identified
by multiplex PCR in 26% of exacerbations (picornavirus, n 5
14; parainfluenza virus, n 5 3; influenza A, n 5 1; RSV, n 5 1;
adenovirus, n 5 1). Mean viral symptom score was 3.4 in PCR-
negative and 4.4 in PCR-positive AECOPD; 23% of patients
with AECOPD had a viral symptom score of greater than or
equal to 4 in the absence of a positive PCR, and were therefore
considered to have a probable viral infection. Bacteria were
identified on sputum culture in 38% of exacerbations;
H. influenzae (n 5 9), P. auruginosa (n 5 7), and S. pneumoniae
(n 5 5) were prominent. Coinfection with both virus and
bacteria identified on pathology samples occurred in 15% of
AECOPD. Both CRP and SAA levels were elevated in
bacteria-associated AECOPD versus nonbacterial AECOPD,
although only SAA levels in coinfection events was significantly
different from noninfective episodes (Figures 8B–8C). We also
assessed the value of acute changes in CRP and SAA to predict
bacterial infection using logistic regression. Specifically, the
odds of a bacterial AECOPD, irrespective of the cut-point
used, increased 57% per 1-unit increase in loge CRP (odds ratio,
1.57; 95% CI, 1.03–2.39; P 5 0.036), and increased 39% per 1-
unit increase in logeSAA (odds ratio, 1.39; 95% CI, 1.04–1.84;
P 5 0.022).
Serum CRP, SAA, and IL-6 Levels during an AECOPD
A table comparing first events to all events (including patients with
multiple exacerbations) is presented in the online supplement.
Figure 7. Individual behavior of associated with serum
amyloid A (SAA) versus C-reactive protein (CRP) in
patients experiencing recurrent acute exacerbations of
chronic obstructive pulmonary disease (AECOPD). The
graph shows four patient profiles selected randomly from
a subgroup of patients in GOLD (Global Initiative for
Chronic Obstructive Lung Disease) class 3–4 experiencing
multiple AECOPD during the longitudinal study. Note
that, whereas SAA and CRP are broadly concordant, they
are dissociated in some events. Rec 5 recovery; St 5
stable; Roman numerals (I–III) in parentheses denote
severity grade.
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It is noteworthy that the inclusion of patients with recurrent
exacerbations would not have biased this result. When the anal-
ysis was restricted to one exacerbation per subject, the data
showed strong evidence of within-subject increase in both SAA
and CRP levels from ‘‘stable’’ to ‘‘acute.’’ Specifically, SAA
levels increased by a ratio of 3.70 (95% CI, 1.87–7.32; P ,
0.001), whereas CRP levels increased by a ratio of 2.60 (95% CI,
1.52–4.43; P , 0.001). There was a significant increase in serum
IL-6 at onset of AECOPD (log AECOPD/COPD ratios, 1.54;
95% CI, 1.10–2.16; P , 0.05). The absolute median value for
stable COPD was 3.6 (95% CI, 4.6–8.0) versus 5.6 for AECOPD
(95% CI, 3.1–38.2; P , 0.05), but there was no significant in-
crease in procalcitonin, which rose in only one patient with con-
firmedpneumonia.The results and conclusionswere similarwhen
we assessed data on all exacerbations (including multiple exac-
erbations in some individuals) using a linear regression model
based upon a GEE that corrects for within-subject correlation of
repeated measures within and between exacerbations (see online
supplement).
Predicting severe AECOPD using the ratio of AECOPD onset
to stable baseline values for each inflammatory marker. For IL-6,
theAUCvalue for the ratio ofAECOPDonset to stable IL-6was
0.59 (95% CI, 0.41–0.78), and was not informative. The SAA
AUC of 0.84 (95%CI, 0.74–0.94) was significantly different from
the CRP AUC of 0.71 (95% CI, 0.56–0.87; P , 0.05). At a cut-
point of a twofold change in inflammatory marker levels, CRP
was 80% sensitive and 54% specific, with a positive likelihood
ratio of 1.73 and a negative likelihood ratio of 0.37. A twofold
change in SAA was 100% sensitive and 44% specific, with
a positive likelihood ratio of 1.80 and negative likelihood ratio
of 0.00. These data indicate that, if a twofold change in SAA is not
observed at the onset ofAECOPD, a severeAECOPD (level III;
respiratory failure) can be excluded. In contrast, a twofold change
in CRP was both less sensitive and less specific, and alternative
cut-off points did not improve its diagnostic precision. If the
cutoff was increased to a 4.6-fold change in SAA, the specificity
increased from 44 to 68%, whereas the sensitivity remained high
(93%). At the same 4.6-fold change cut-point, CRP was 60%
sensitive and 74% specific.
Combining SAA or CRP with clinical symptoms to predict
severe AECOPD. We analyzed whether change in a major symp-
tom (dyspnea severity; sputum purulence or volume) (23, 31) at
onset of AECOPDwas predictive of severe AECOPD. CRPwas
no better then dyspnea (P 5 0.51) or Anthonisen criteria (P 5
0.60) in predicting severe episodes, whereas SAA proved to be
significantly better than dyspnea (P5 0.01) andAnthonisen (P5
0.04). Using logistic regression to combine CRP or SAA with
amajor symptomdid not improve the predictionmodel for severe
AECOPD over SAA alone. This indicates that SAA is a highly
sensitive and specific marker of severe AECOPD that is discrim-
inative even in the absence of additional clinical information.
DISCUSSION
In this article, we have identified SAA as a novel blood bio-
marker of AECOPD. Our data show that change in SAA is
associated with event severity, and SAA was found to have
greater sensitivity and specificity in describing AECOPD than
did CRP when assessed by ROC. Our data indicate that a four-
fold or greater increase above basal in SAAalonewas associated
with severe AECOPD, and this discriminative value was not
further improved by combining SAA with major clinical signs
(dyspnea and sputum). SAA levels may therefore be a useful
adjunct in the objective early identification and management of
AECOPD, and may also help to identify those patients at
greatest risk of respiratory failure in most need of hospitaliza-
tion. The inflammatory markers, IL-6 and procalcitonin, which
have been used to guide antibiotic treatment in pneumonia (32),
were uninformative.
The association of change in SAA with severity is of consider-
able interest, as objectively grading the severity of AECOPD
is difficult. Current approaches use a combination of functional
criteria, clinical symptoms, and measurements (9). Objective
surrogates of severity have proven difficult to identify. In a meta-
analysis of 268 studies involving 142,407 patients, Franciosi and
colleagues (30) found that only arterial CO2 and respiratory rate
were potential surrogates for severity. Pinto-Plata and colleagues
have recently reported the clinical association of serum IL-6, TNF,
and IL-8 with clinical indices of severity (33, 34). CRP is known
to rise acutely during infective AECOPD (35), and its levels may
also represent a useful predictor of exacerbations when combined
with clinical signs, notably dyspnea (31).ConsistentwithHurst and
colleagues (31) we found that CRP rise was not significantly asso-
ciated with event severity. Further prospective research will be
necessary to determine the role of SAA as a predictor of event
severity.
Figure 8. Elevated serum amyloid A (SAA) during acute exacerbations
of chronic obstructive pulmonary disease (AECOPD) is associated with
the presence of a viral and bacterial pathogen. (A) Pathogens identified
by multiplex polymerase chain reaction (PCR) or sputum culture were
grouped according to the presence of bacteria alone, both bacteria and
virus, virus alone, or no pathogen detected (NPD) during exacerbation.
Episodes negative by multiplex PCR or sputum culture with significant
infectious symptoms were graded as clinically bacterial or viral (see
METHODS for details). Absolute SAA (B) and C-reactive protein (CRP) (C)
values at AECOPD onset were also grouped according to pathogen
type. Data points represent individual patients, and the bar denotes
median values. #P , 0.05, analysis of variance.
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We found that SAA was associated with infection. The
present study is consistent with the recent findings of Papi and
colleagues, who showed that AECOPD severity tracks with
increased airway inflammation (13). Almost all these exacerba-
tions were associated with proven infection or signs of infection
(13). Like CRP, SAA is induced in the liver by IL-1b and IL-6,
the levels of which are known to rise in AECOPD (14, 36).
Accordingly, increases in SAA have previously been reported in
a number of inflammatory diseases (37, 38) and in viral lung
infections, including severe acute respiratory syndrome (39). We
found that SAA was modestly elevated at baseline. To our
knowledge, there has been no previous systematic study of SAA
in COPD or AECOPD. Nel and colleagues reported acute-phase
changes in bronchiectasis and bronchial carcinoma (40); Gao and
colleagues reported twofold elevations of SAA in lung cancer
(protein array), but not in COPD (41); Parnham and colleagues
reported SAA in the normal range (,5 mg/L) in stable disease
(42); Falsey and colleagues reported three patients with elevated
SAA 4 weeks after influenza infection (43). Elevated SAA was
also found in patients with cardiovascular disease where COPD
was a comorbidity (44). About half of all deaths from COPD are
associated with cardiovascular events, and the incidence of such
events increases markedly after AECOPD (4, 45). Because SAA
level is a good predictor of coronary artery disease and a strong
predictor of future cardiovascular events in women (44), we also
speculate that blocking SAA or its actions may be of therapeutic
benefit in COPD, AECOPD, and, possibly, comorbid cardiovas-
cular disease.
As both CRP and SAA are induced in the liver by the same
inflammatory cytokines, their differential behavior in our
study is interesting. The main difference between SAA and
CRP production is that SAA can also be produced extrahe-
patically in inflamed tissue (26, 46, 47). This raises the pos-
sibility that SAA production in the inflamed lung, as well as
hepatic SAA, may have contributed to the SAA that we
measured in this study. Consistent with this possibility, SAA,
but not CRP, has recently been detected in the lungs of smoke-
exposed, endotoxin-challenged mice, and SAA has been
identified, but not quantified, in bronchoalveolar lavage fluid
of smokers with COPD using high-sensitivity proteomics (48,
49). It is currently not possible to reliably detect SAA in
sputum, and we are developing methods to test this possibility
during AECOPD. This would also allow direct comparison to
be made with sputum inflammatory indices and sputum virol-
ogy and bacteriology.
Our study also raises the issue of whether SAA is a marker
or a mediator of AECOPD. There is now extensive evidence
that CRP is both a marker and a likely mediator of disease.
SAA directly binds gram-negative bacteria and acts as an innate
immune opsonin, leading to enhanced clearance of pathogens,
which suggests a beneficial role (50). However, SAA has direct
proinflammatory activities by inducing activation and chemo-
taxis of neutrophils and other inflammatory cells (51–53),
promoting release of matrix metalloproteases (54), and in-
ducing proinflammatory cytokines, including those in the IL-
17/IL-23 axis now implicated in mediating neutrophil inflam-
mation (55, 56). Surprisingly, SAA is also a G-protein–coupled
receptor (FPLR1/LXA4R) agonist. The FPLR1/LXA4R re-
ceptor is unusual, because it is shared by two ligands, both the
inflammatory bacterial formyl peptide and also the antiinflam-
matory eicosanoid, lipoxin A4 (57). Lipoxins have recently been
recognized as important inflammation-resolving mediators.
Furthermore, it has very recently been discovered that SAA
promotes neutrophil survival via P2X7 purinergic receptors
independently of FPLR1 (58). SAA could therefore both
worsen inflammation and, we speculate, blunt resolution of
inflammation by interfering with lipoxin signaling, collectively
intensifying or prolonging AECOPD. This possibility remains
to be tested. Although we found that systemic steroids had no
acute effect on SAA, SAA levels measured longitudinally might
also be a surrogate marker for the efficacy of other COPD
treatments.
There are a number of caveats to this initial study. We
analyzed both change in biomarker levels and absolute amount,
and found identical statistical outcomes. Similarly, we found
that stable SAA levels in this study (7.7 mg/L) were modestly
higher than the normal range (1–5 mg/L), and we calculated
absolute value ‘‘diagnostic cut-off’’ levels from ROC curves.
However, until replicated independently and further validated
independently, it would be injudicious to use the SAA absolute
values reported here to guide practice. SAA performed best
when change from basal levels were determined early in the
course of an AECOPD, as the ROC values in the longitudinal
substudy (2.3 d from onset of symptoms to collection of sample)
were higher than the those in the cross-sectional study (6.7-d lag).
In the future, SAA may emerge as a particularly well-suited
biomarker for at-home, community-based, or early generalist
point-of-care disease management approaches. SAA might also
form part of a panel of markers analyzed in an algorithm,
because the feasibility of protein miniarray methods in
AECOPD has now been demonstrated by Pinto-Plata and
colleagues (33, 34). RSV rates were consistent with those that
we have previously reported in this cohort and the community
rate recorded during the study period (Infectious Disease
Reference Laboratory), but are lower than those reported in
the East London cohort (59). Although almost all of our
patients were being treated with an inhaled, long-acting b-
adrenoceptor agonist/steroid combination, it is known that SAA
induction is not suppressed by glucocorticosteroids in vitro or
in vivo (60, 61). We also found no acute affect of oral prednis-
olone or intravenous hydrocortisone on SAA when we directly
tested this possibility. Further validation will also be required in
patient populations excluded from the present study, such as
those with mild disease or comorbid, chronic, systemic inflam-
matory conditions. In the cross-sectional study, many of our
patients with AECOPD developed fluid overload, and it would
be of some interest to study whether combining SAA with b
naturetic peptide, a marker of heart failure, might be useful to
distinguish these distinct causes of breathlessness (62). 27% of
our subjects had congestive heart failure. However, future stud-
ies would need to account for potentially confounding elevated
b naturetic peptide secondary to right heart failure to pulmo-
nary hypertension, which is common in COPD. Procalcitonin
has also been suggested as a marker of severity, but we did not
find it informative, perhaps because procalcitonin levels might
better reflect pneumonia than AECOPD severity (32, 63, 64).
Copeptin, the precursor of vasopressin, has also recently been
described as a possible biomarker of type III AECOPD (63, 64).
It would also be particularly useful to discover other biomarkers
that can be combined with SAA to distinguish bacterial from
viral infectious causes of AECOPD. IFN-g–inducible 10-kD pro-
tein is one possibility that is an area of ongoing research in our
group (65).
In conclusion, our data identify SAA as a novel biomarker of
AECOPD, the levels of which are related to event severity.
Accordingly, SAA may have utility in the clinical identification,
classification, and management of AECOPD. We propose that
the biology of SAA may also offer new insights into pathogenic
mechanisms in COPD and AECOPD.
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